LOUISVILLE, Ky., Dec. 5 /PRNewswire/ -- Potentia Pharmaceuticals, Inc. announced today the appointment of Armen H. Tashjian, Jr., M.D. to its Scientific Advisory Board.
Dr. Tashjian is Professor of Biological Chemistry and Molecular Pharmacology, emeritus at Harvard Medical School where his research focuses on the biochemical and molecular mechanisms of signal transduction with an emphasis on neuropeptides and their receptors. A second long-term interest has been on intracellular and extracellular calcium metabolism and skeletal biology and pharmacology. He founded the Department of Molecular and Cellular Toxicology at the Harvard School of Public Health where he is Professor of Toxicology, emeritus. Under his guidance, this department was at the forefront of discovering mechanisms of toxicity of environmental chemicals and therapeutic agents.
Dr. Tashjian has been an officer in numerous scientific societies, serving on NIH study sections and government advisory panels, and on the editorial boards of over 15 scientific journals including the New England Journal of Medicine. He is a senior advisor to a number of pharmaceutical and biotechnology companies, and venture capital funds. He is an elected member of the Norwegian Academy for Science and Letters and is Deputy Editor of the recently published textbook entitled Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy.
"We are excited that Dr. Tashjian has agreed to join Potentia's Scientific Advisory Board," said Cedric Francois, M.D., Ph.D., Chief Executive Officer for Potentia. "He has a stellar record of accomplishment and brings years of scientific leadership to Potentia."
About Potentia Pharmaceuticals, Inc.
Potentia Pharmaceuticals, Inc. (http://www.potentiapharma.com) is a private, development-stage biotechnology company based in Louisville, KY and with operations in Boston, MA and Santa Fe, NM. Together with its corporate and academic partners, Potentia is developing new approaches to the treatment of ocular chronic inflammatory diseases such as age-related macular degeneration, diabetic retinopathy, and uveitis.
This press release contains "forward-looking statements" regarding the potential therapeutic benefits and progress of Potentia's research and development programs. These statements are hereby identified as "forward- looking statements". Forward-looking statements include statements regarding Potentia's expectations, beliefs, intentions or strategies regarding the future and include statements containing forward-looking words such as "anticipate", "believe", "could", "estimate", "expect", "intend", "may", "should", "will", and "would" or similar words. Such statements are based on our management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward looking statements as a result of many factors, including, without limitation, uncertainties relating to drug discovery; formulation development; clinical development processes; enrollment rates for patients in our clinical trials; changes in relationships with strategic partners and dependence upon strategic partners for the performance of certain activities under collaborative agreements; the impact of competitive products and technological changes; uncertainties relating to patent protection and uncertainties relating to our ability to obtain funding. Potentia disclaims any intent or obligation to update this press release or forward-looking statements contained therein.
Our logo, trademarks, and service marks are the property of Potentia Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Potentia Pharmaceuticals, Inc.CONTACT: Pascal Deschatelets, Chief Operating Officer of Potentia,+1-502-569-1053
Web site: http://www.potentiapharma.com//
